- Stocks
- Pharma & Healthcare
- Medicamen Biotech
Medicamen Biotech share price
NSE: MEDICAMEQPharma & HealthcareDrug Manufacturers - Specialty & Generic
Medicamen Biotech at a glance
Medicamen Biotech (NSE: MEDICAMEQ) closed at ₹266.50 on 22 Oct 2026, down 0.11% on the day. With a market capitalisation of ₹361 Cr, it ranks 1954th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 36.9× trailing earnings, against a return on equity of 3.5% in FY26. Over the past year the share price has fallen 14.0%. Its 52-week range is ₹212.40 (29 Jun 2026) to ₹447.65 (25 Nov 2025); the last close is 40.5% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹61 Cr (+104.8% year on year) and net profit ₹4 Cr (+139.2%), on a consolidated basis. Promoters held 40.46% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹361 CrRank 1954 on NSE
- P/E (trailing)
- 36.9×
- Price to book
- 1.11×FY26
- EPS (TTM)
- ₹7.23to Q4 FY26
- ROE
- 3.5%FY26
- ROCE
- 5.5%FY26
- Debt to equity
- 0.17FY26
- Net profit margin
- 5.0%FY26
- Book value / share
- ₹203.17FY26
- 52-week high
- ₹447.6525 Nov 2025
- 52-week low
- ₹212.4029 Jun 2026
- 1-year return
- −14.0%
- RSI (14-day)
- 33.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.11% | −10.6% | −16.8% | +7.7% | −14.0% |
Medicamen Biotech quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹43 Cr | ₹45 Cr | ₹45 Cr | ₹30 Cr | ₹43 Cr | ₹47 Cr | ₹47 Cr | ₹61 Cr |
| Revenue YoY | +2.6% | +2.8% | −2.9% | −37.4% | −0.0% | +5.4% | +3.9% | +104.8% |
| Net profit | ₹1 Cr | ₹1 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹4 Cr |
| Net profit YoY | −79.7% | −39.2% | +43.8% | −8.8% | +100.0% | +134.4% | −44.2% | +139.2% |
| Net margin | 1.9% | 2.0% | 6.5% | 6.3% | 3.7% | 4.5% | 3.5% | 7.3% |
| EPS | ₹0.63 | ₹0.71 | ₹2.30 | ₹1.47 | ₹1.18 | ₹1.56 | ₹1.21 | ₹3.28 |
Medicamen Biotech financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹113 Cr | ₹115 Cr | ₹141 Cr | ₹179 Cr | ₹163 Cr | — |
| Operating profit | ₹16 Cr | ₹18 Cr | ₹17 Cr | ₹13 Cr | ₹10 Cr | — |
| Net profit | ₹12 Cr | ₹15 Cr | ₹15 Cr | ₹9 Cr | ₹7 Cr | — |
| EPS (₹) | ₹10.00 | ₹12.00 | ₹12.00 | ₹8.00 | ₹5.00 | — |
| Cash from operations | ₹13 Cr | ₹4 Cr | −₹6 Cr | −₹7 Cr | −₹8 Cr | — |
| Total debt | ₹6 Cr | ₹5 Cr | ₹1 Cr | ₹1 Cr | ₹4 Cr | ₹6 Cr |
| Shareholders' equity | ₹133 Cr | ₹146 Cr | ₹191 Cr | ₹207 Cr | ₹213 Cr | ₹276 Cr |
Medicamen Biotech shareholding pattern
| Holder | 24 Apr 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% |
| Foreign institutions | 0.22% | 0.00% | 0.06% | 0.02% | 0.10% | 0.07% |
| Domestic institutions | 0.65% | 0.64% | 0.59% | 0.44% | — | 0.40% |
| Non-institutions | 58.62% | 58.84% | 58.85% | 59.03% | 59.39% | 59.02% |
Medicamen Biotech vs peers
The listed Pharma & Healthcare companies nearest to Medicamen Biotech by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| JENBURPHJenburkt Pharma | ₹898.80 | +0.98% | — | ₹397 Cr | 11.4 | — |
| TRANSCHEMTranschem | — | — | — | ₹391 Cr | — | — |
| APPLAptus Pharma | — | — | — | ₹377 Cr | — | — |
| MEDICAMEQMedicamen Biotech | ₹266.50 | −0.11% | −14.0% | ₹361 Cr | 36.9 | — |
| ASTALLTDAstal Lab | — | — | — | ₹358 Cr | — | — |
| NURECANureca | ₹338.50 | +2.92% | +44.4% | ₹323 Cr | 159.7 | — |
| AAREYDRUGSAarey Drugs & Pharmaceuticals | ₹111.75 | −0.84% | +31.2% | ₹317 Cr | 80.4 | — |
Ask anything about Medicamen Biotech
Pivot answers on the live chart with evidence you can check, and tests strategies against MEDICAMEQ's own history. Try: “Why has MEDICAMEQ moved over the last three months?” · “Backtest a 50-day moving-average crossover on MEDICAMEQ over five years” · “Compare MEDICAMEQ with JENBURPH on margins and valuation”
Frequently asked questions about Medicamen Biotech
What is the share price of Medicamen Biotech today?
Medicamen Biotech (NSE: MEDICAMEQ) last closed at ₹266.50 on 22 Oct 2026. Its 52-week high is ₹447.65 and its 52-week low is ₹212.40.
What is the market cap of Medicamen Biotech?
Medicamen Biotech's market capitalisation is ₹361 Cr (₹361 Cr) at the 22 Oct 2026 close, ranking 1954th among the NSE companies Pivot tracks.
What is the P/E ratio of Medicamen Biotech?
Medicamen Biotech trades at a trailing P/E of 36.9. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 80.4.
What is the ROE and ROCE of Medicamen Biotech?
Return on equity was 3.5% in FY26 and return on capital employed was 5.5% in FY26 (consolidated figures).
Is Medicamen Biotech a debt-free company?
No. Medicamen Biotech's debt-to-equity ratio was 0.17 in FY26, with total debt of ₹6 Cr.
What were Medicamen Biotech's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Medicamen Biotech reported revenue of ₹61 Cr, +104.8% year on year, and net profit of ₹4 Cr, +139.2% year on year.
How has Medicamen Biotech stock performed over the last year?
Medicamen Biotech's share price has fallen 14.0% over the past year, +7.7% over three months and −16.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Medicamen Biotech?
As of 30 Jun 2026: promoters 40.46%, foreign institutions 0.07%, domestic institutions 0.40%, non-institutions 59.02%.
Who are Medicamen Biotech's competitors?
The listed Pharma & Healthcare companies closest to Medicamen Biotech by market cap are Jenburkt Pharma, Transchem, Aptus Pharma, Astal Lab, Nureca and Aarey Drugs & Pharmaceuticals.
Is Medicamen Biotech a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Medicamen Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MEDICAMEQ against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text